SCHEMBL211832

SCHEMBL211832

Cc1ccc2[nH][c]nc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
POLB P06746 1/20 0.38
CYP1A2 P05177 3/20 0.38
NQO2 P16083 1/20 0.38
MAPT P10636 2/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 3/20 0.34
ACHE P22303 1/20 0.34
CHEK1 O14757 1/20 0.34
PARP1 P09874 1/20 0.34
PIM1 P11309 1/20 0.34
RPS6KA3 P51812 1/20 0.34
USP2 O75604 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
MEN1 O00255 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967417 0.83 KMT2A (0.42) KMT2APOLBCYP1A2NQO2MAPT
SCHEMBL206867 0.75 NOS1 (0.38) CYP1A2ALDH1A1CHEK1PIM1RPS6KA3
SCHEMBL208893 0.75 KDM4E (0.36) KMT2ACYP1A2MAPTKDM4EALDH1A1
SCHEMBL207659 0.75 F7 (0.42) KMT2APOLBMAPTKDM4EALDH1A1
SCHEMBL5981619 0.75 DYRK1A (0.42) KMT2APOLBMAPTKDM4EALDH1A1
SCHEMBL7221951 0.75 ALDH1A1 (0.42) KMT2APOLBKDM4EALDH1A1CHEK1
SCHEMBL15157341 0.75 KIF11 (0.40) ALDH1A1HPGDHTR1A
SCHEMBL5981617 0.75 TERT (0.47) MAPTKDM4EALDH1A1
SCHEMBL356787 0.75 MEN1 (0.46) KMT2APOLBCYP1A2NQO2MAPT
SCHEMBL416318 0.74 FABP6 (0.41) KMT2APOLBCYP1A2NQO2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2362775-B1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2015-08-05 EP claimed
US-8697685-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2014-04-15 US claimed
EP-1720835-B1 NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS NYCOMED GMBH (DE) 2012-12-12 EP claimed
US-20110275611-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2011-11-10 US claimed
EP-2362775-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2011-09-07 EP claimed
JP-4728259-B2 2011-07-20 JP claimed
WO-2010059658-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO claimed
US-20080207683-A1 BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-28 US claimed
US-20070167482-A1 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors ALTANA PHARMA AG (DE) 2007-07-19 US claimed
EP-1720835-A1 NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS Altana Pharma AG (DE) 2006-11-15 EP claimed
US-20060116518-A1 Novel phenanthridines ALTANA PHARMA AG (DE) 2006-06-01 US claimed
EP-1581533-A2 NOVEL BENZONAPHTHYRIDINES ALTANA Pharma AG (DE) 2005-10-05 EP claimed
WO-2004018465-A9 BENZONAPHTHYRIDINES WITH PDE 3/4 INHIBITING ACTIVITY ALTANA PHARMA AG (DE) 2005-09-15 WO claimed
WO-2005077906-A1 NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENENTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS ALTANA PHARMA AG (DE) 2005-08-25 WO claimed
EP-1537086-A2 NOVEL PHENANTHRIDINES ALTANA Pharma AG (DE) 2005-06-08 EP claimed
WO-2004018431-A2 NOVEL PHENANTHRIDINES ALTANA PHARMA AG (DE) 2004-03-04 WO claimed
WO-2004018465-A2 BENZONAPHTHYRIDINES WITH PDE 3/4 INHIBITING ACTIVITY ALTANA PHARMA AG (DE) 2004-03-04 WO claimed
CN-1225013-A Non-peptide G-CSF mimetics SMITHKLINE BEECHAM CORP (US) 1999-08-04 CN claimed
US-11944618-B2 Subcutaneous delivery of polymer conjugates of therapeutic agents SERINA THERAPEUTICS, INC. (US) 2024-04-02 US disclosed
EP-0012909-A1 Benzimidazolyl-2-alkane-phosphonic acids and their salts, process for their preparation and their use as corrosion inhibitors or wetting agents BAYER AG (DE) 1980-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11944618-B2 Subcutaneous delivery of polymer conjugates of therapeutic agents CD44, CD47, LNPEP KMT2A 2825/4885POLB 1954/4885CYP1A2 4666/4885
US-20110275611-A1 CHEMICAL COMPOUNDS PDK1, PDK2, PDK3 KMT2A 2173/4885POLB 3721/4885CYP1A2 1859/4885
US-20070167482-A1 Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors PDE4A, PDE3A, PDE4B KMT2A 2822/4885POLB 2755/4885CYP1A2 483/4885
US-20060116518-A1 Novel phenanthridines PDE4A, PDE4B, PDE3A KMT2A 2155/4885POLB 2416/4885CYP1A2 185/4885
US-20080207683-A1 BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ KMT2A 4149/4885POLB 2119/4885CYP1A2 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.